drugset / Trial / NCT04210713
Neuroimmune Dysfunction in Alcohol Use Disorder
Phase 1
Completed
142 enrolled
University of Maryland, Baltimore
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.
Timeline
- Start
- 2020-02-03
- Primary completion
- 2023-09-20
- Completion
- 2023-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Minocycline | Small molecule | 200 mg | — |